BTIG Thinks Valeant (VRX) Should Just Severe Ties with Philidor; PT Cut to $175
Tweet Send to a Friend
BTIG is cutting its price target on Valeant Pharma (NYSE: VRX) from $210 down to $175, but maintaining a Buy ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
